Colony Group LLC raised its holdings in Core Laboratories N.V. (NYSE:CLB) by 9.4% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 37,190 shares of the oil and gas company’s stock after buying an additional 3,183 shares during the period. Colony Group LLC owned approximately 0.08% of Core Laboratories worth $3,671,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. Sustainable Growth Advisers LP raised its holdings in shares of Core Laboratories by 36.9% in the 2nd quarter. Sustainable Growth Advisers LP now owns 2,345,271 shares of the oil and gas company’s stock valued at $237,505,000 after purchasing an additional 632,263 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Core Laboratories by 141.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 567,306 shares of the oil and gas company’s stock valued at $55,992,000 after purchasing an additional 332,620 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC raised its holdings in shares of Core Laboratories by 19.0% in the 3rd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 2,025,357 shares of the oil and gas company’s stock valued at $199,904,000 after purchasing an additional 323,357 shares in the last quarter. WCM Investment Management CA raised its holdings in shares of Core Laboratories by 7.3% in the 2nd quarter. WCM Investment Management CA now owns 4,433,175 shares of the oil and gas company’s stock valued at $448,948,000 after purchasing an additional 303,073 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its holdings in shares of Core Laboratories by 1,087.6% in the 3rd quarter. Ameriprise Financial Inc. now owns 315,556 shares of the oil and gas company’s stock valued at $31,143,000 after purchasing an additional 288,985 shares in the last quarter.

Several equities research analysts recently commented on CLB shares. Deutsche Bank started coverage on shares of Core Laboratories in a research note on Tuesday, October 10th. They set a “buy” rating and a $109.00 price target on the stock. Zacks Investment Research lowered shares of Core Laboratories from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Scotiabank set a $136.00 price target on shares of Core Laboratories and gave the stock a “hold” rating in a research note on Wednesday, October 25th. Royal Bank of Canada cut their price target on shares of Core Laboratories from $115.00 to $112.00 and set an “outperform” rating on the stock in a research note on Thursday, September 7th. Finally, ValuEngine lowered shares of Core Laboratories from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the company’s stock. Core Laboratories presently has an average rating of “Hold” and an average price target of $110.40.

Core Laboratories N.V. (CLB) opened at $101.74 on Tuesday. Core Laboratories N.V. has a 52-week low of $86.55 and a 52-week high of $125.83. The company has a debt-to-equity ratio of 1.53, a quick ratio of 1.81 and a current ratio of 2.18. The stock has a market cap of $4,458.88, a price-to-earnings ratio of 55.19 and a beta of 1.56.

Core Laboratories (NYSE:CLB) last issued its quarterly earnings data on Monday, October 23rd. The oil and gas company reported $0.48 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.44 by $0.04. Core Laboratories had a net margin of 12.06% and a return on equity of 52.89%. The company had revenue of $166.20 million for the quarter, compared to the consensus estimate of $160.94 million. During the same period last year, the firm posted $0.38 EPS. Core Laboratories’s revenue for the quarter was up 1.4% on a year-over-year basis. equities analysts anticipate that Core Laboratories N.V. will post 1.99 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, November 21st. Stockholders of record on Friday, October 20th were issued a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 2.16%. The ex-dividend date was Thursday, October 19th. Core Laboratories’s payout ratio is 126.44%.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.watchlistnews.com/colony-group-llc-acquires-3183-shares-of-core-laboratories-n-v-clb/1759277.html.

About Core Laboratories

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories N.V. (NYSE:CLB).

Institutional Ownership by Quarter for Core Laboratories (NYSE:CLB)

Receive News & Ratings for Core Laboratories N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories N.V. and related companies with MarketBeat.com's FREE daily email newsletter.